BURLINGTON, ON, Sept. 26, 2012 /CNW/ - One of the greatest challenge
facing North American health care today is diabetes. It is estimated
that there are 60 million diabetics in North American in 2012 and that
number is climbing rapidly. Approximately 65% of diabetics will develop
peripheral neuropathy, a painful and often irreversible condition
affecting both lower limbs. It begins as tingling and mild pain in the
feet and eventually it becomes painless as the nerve function is
compromised and sensation is lost. The loss of nerve function and
decreased vascularity in the lower limb makes the patient susceptible
to ulcers and wounds on the foot that will heal very slowly if at all.
This opens up the risk for infection and greatly increases the
likelihood of amputation. The cost in human terms and in financial
terms to the health care system is staggering. It is estimated there is
an amputation every 30 seconds in North America.
NeuroVasc Clinical Inc. has brought a solution to the North American
market place. The patented technology called FREMS is an FDA and Health
Canada approved device that uses a patented electrical frequency and
duty cycle to stimulate blood vessel re-growth and tissue regeneration
in tissue that has compromised nerve and blood vessel function. The
patient is treated 10 times once daily for 40 minutes and the effects
on the tissue will last up to 18 month depending on the overall health
of the patient. Thus this treatment becomes part of the maintenance of
the lower limb for the diabetic patient as they age and will be a key
player in the prevention of painful neuropathy and the development of
Each FREMS device can treat approx. 8-10 patients a day.
The sale of each FREMS device will generate approx. $ 8,000 of gross
profit for EKO
Consumable supplies for each treatment will generate approx. $3.00 of
gross profit for EKO
NeuroVasc Clinical will be partnering with leading doctors and clinics
in North America to provide this service locally. Training and patient
education will be provided centrally by NeuroVasc Clinical and
treatment will be provided at clinics certified by NeuroVasc Clinical
Each FREMS device is expected to generate between $1,000 and $1,500
gross income per day for the clinics which are recommended to operate
3-5 devices per clinic.
NeuroVasc Clinical is committed to seeking out world class partners and
helping them provide this invaluable service to the diabetic population
to prevent unwanted illness and even early mortality.
SOURCE: EKO INTERNATIONAL CORP.
For further information:
To contact the company by e-mail, please use email@example.com